Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway.

The transcription factor nuclear factor-kappaB (NF-kappaB) plays an important role in regulating cell growth, apoptosis, and metastatic functions. Constitutive activation of NF-kappaB has been observed in various cancers; however, molecular mechanisms resulting in such activation remain elusive. Based on our previous results showing that drug-resistant and metastatic cancer cells have high levels of tissue transglutaminase (TG2) expression and that this expression can confer chemoresistance to certain types of cancer cells, we hypothesized that TG2 contributes to constitutive activation of NF-kappaB. Numerous lines of evidence showed that overexpression of TG2 is linked with constitutive activation of NF-kappaB. Tumor cells with overexpression of TG2 exhibited increased levels of constitutively active NF-kappaB. Activation of TG2 led to activation of NF-kappaB; conversely, inhibition of TG2 activity inhibited activation of NF-kappaB. Similarly, ectopic expression of TG2 caused activation of NF-kappaB, and inhibition of expression of TG2 by small interfering RNA abolished the activation of NF-kappaB. Our results further indicated that constitutive NF-kappaB reporter activity in pancreatic cancer cells is not affected by dominant-negative I kappaB alpha. Additionally, coimmunoprecipitation and confocal microscopy showed that I kappaB alpha is physically associated with TG2. Lastly, immunohistochemical analysis of pancreatic ductal carcinoma samples obtained from 61 patients further supported a strong correlation between TG2 expression and NF-kappaB activation/overexpression (P = 0.0098, Fisher's exact test). We conclude that TG2 induces constitutive activation of NF-kappaB in tumor cells via a novel pathway that is most likely independent of I kappaB alpha kinase. Therefore, TG2 may be an attractive alternate target for inhibiting constitutive NF-kappaB activation and rendering cancer cells sensitive to anticancer therapies.

[1]  K. Mehta,et al.  Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells , 2006, Oncogene.

[2]  S. Gravel,et al.  The Proinflammatory Actions of Angiotensin II Are Dependent on p65 Phosphorylation by the IκB Kinase Complex* , 2006, Journal of Biological Chemistry.

[3]  Suresh Mishra,et al.  The p53 oncoprotein is a substrate for tissue transglutaminase kinase activity. , 2006, Biochemical and biophysical research communications.

[4]  J. Pan,et al.  Retinoic acid receptors and tissue-transglutaminase mediate short-term effect of retinoic acid on migration and invasion of neuroblastoma SH-SY5Y cells , 2006, Oncogene.

[5]  K. Mehta.  Mammalian transglutaminases: a family portrait. , 2005, Progress in experimental tumor research.

[6]  G. Melino,et al.  Tissue transglutaminase (TG2) acting as G protein protects hepatocytes against Fas‐mediated cell death in mice , 2005, Hepatology.

[7]  Masakazu Toi,et al.  Nuclear factor-κB inhibitors as sensitizers to anticancer drugs , 2005, Nature Reviews Cancer.

[8]  R. Eckert,et al.  Transglutaminases : family of enzymes with diverse functions , 2005 .

[9]  A. Sahin,et al.  Prognostic Significance of Tissue Transglutaminase in Drug Resistant and Metastatic Breast Cancer , 2004, Clinical Cancer Research.

[10]  T. Joh,et al.  Transglutaminase 2 induces NF-κB activation via a novel pathway in BV-2 microglia , 2004 .

[11]  R. Cerione,et al.  Augmentation of Tissue Transglutaminase Expression and Activation by Epidermal Growth Factor Inhibit Doxorubicin-induced Apoptosis in Human Breast Cancer Cells* , 2004, Journal of Biological Chemistry.

[12]  B. Aggarwal,et al.  Nuclear factor-kappaB: the enemy within. , 2004, Cancer cell.

[13]  M. Konopleva,et al.  Drug‐resistant breast carcinoma (MCF‐7) cells are paradoxically sensitive to apoptosis , 2004, Journal of cellular physiology.

[14]  W. Greene,et al.  p53 Induces NF-κB Activation by an IκB Kinase-independent Mechanism Involving Phosphorylation of p65 by Ribosomal S6 Kinase 1* , 2004, Journal of Biological Chemistry.

[15]  R. Mansel,et al.  Expression of transglutaminases in human breast cancer and their possible clinical significance. , 2003, Oncology reports.

[16]  B. Aggarwal,et al.  Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-κB activation through inhibition of IκBα kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin D1 , 2003 .

[17]  H. Nakshatri,et al.  NF-κ B Promotes Breast Cancer Cell Migration and Metastasis by Inducing the Expression of the Chemokine Receptor CXCR4* , 2003, Journal of Biological Chemistry.

[18]  Yun-ping Zhu,et al.  Identification of metastasis‐associated proteins by proteomic analysis and functional exploration of interleukin‐18 in metastasis , 2003, Proteomics.

[19]  Robert M. Graham,et al.  Transglutaminases: crosslinking enzymes with pleiotropic functions , 2003, Nature Reviews Molecular Cell Biology.

[20]  Mauro Piacentini,et al.  Transglutaminase 2: an enigmatic enzyme with diverse functions. , 2002, Trends in biochemical sciences.

[21]  B. Aggarwal,et al.  Nuclear factor-kappa B and cancer: its role in prevention and therapy. , 2002, Biochemical pharmacology.

[22]  R. Cerione,et al.  Tissue Transglutaminase Protects against Apoptosis by Modifying the Tumor Suppressor Protein p110 Rb* , 2002, The Journal of Biological Chemistry.

[23]  A. Sahin,et al.  Human breast cancer MCF-7 cell line contains inherently drug-resistant subclones with distinct genotypic and phenotypic features. , 2002, International journal of oncology.

[24]  Michael Karin,et al.  NF-κB in cancer: from innocent bystander to major culprit , 2002, Nature Reviews Cancer.

[25]  K. Mehta,et al.  Multidrug-resistant MCF-7 breast cancer cells contain deficient intracellular calcium pools , 2002, Breast Cancer Research and Treatment.

[26]  Wei Zhang,et al.  Tissue Microarrays: Applications in Neuropathology Research, Diagnosis, and Education , 2002, Brain pathology.

[27]  R. Cerione,et al.  Effects of Tissue Transglutaminase on Retinoic Acid-induced Cellular Differentiation and Protection against Apoptosis* , 2001, The Journal of Biological Chemistry.

[28]  G. Cheng,et al.  Upregulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance, which can be overcome by NF-κB inhibition , 2000, Oncogene.

[29]  A. Ichinose,et al.  [Transglutaminase and apoptosis]. , 2000, Seikagaku. The Journal of Japanese Biochemical Society.

[30]  G. Dong,et al.  Expression of a Dominant-Negative Mutant Inhibitor-κBα of Nuclear Factor-κB in Human Head and Neck Squamous Cell Carcinoma Inhibits Survival, Proinflammatory Cytokine Expression, and Tumor Growth in Vivo , 1999 .

[31]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[32]  L. Thomsen,et al.  Role of nitric oxide in tumour progression: Lessons from human tumours , 1998, Cancer and Metastasis Reviews.

[33]  A. E. Rogers,et al.  Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. , 1997, The Journal of clinical investigation.

[34]  Z. Nemes,et al.  Tissue transglutaminase-dependent posttranslational modification of the retinoblastoma gene product in promonocytic cells undergoing apoptosis , 1997, Molecular and cellular biology.

[35]  G. Sledge,et al.  Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth , 1997, Molecular and cellular biology.

[36]  V. Castronovo,et al.  Highly-expressed p100/p52 (NFKB2) sequesters other NF-kappa B-related proteins in the cytoplasm of human breast cancer cells. , 1995, Oncogene.

[37]  G. Melino,et al.  Tissue transglutaminase and apoptosis: sense and antisense transfection studies with human neuroblastoma cells , 1994, Molecular and cellular biology.

[38]  K. Mehta.  High levels of transglutaminase expression in doxorubicin‐resistant human breast carcinoma cells , 1994, International journal of cancer.

[39]  J. Johnson,et al.  12-O-tetradecanoylphorbol-13-acetate- and tumor necrosis factor alpha-mediated induction of intercellular adhesion molecule-1 is inhibited by dexamethasone. Functional analysis of the human intercellular adhesion molecular-1 promoter. , 1994, The Journal of biological chemistry.

[40]  V. Castronovo,et al.  The NF-kappa B transcription factor and cancer: high expression of NF-kappa B- and I kappa B-related proteins in tumor cell lines. , 1994, Biochemical pharmacology.

[41]  L. Fésüs,et al.  Apoptosis: molecular mechanisms in programmed cell death. , 1991, European journal of cell biology.

[42]  D. Baltimore,et al.  I kappa B: a specific inhibitor of the NF-kappa B transcription factor. , 1988, Science.

[43]  Douglas B. Evans,et al.  Function of Nuclear Factor κB in Pancreatic Cancer Metastasis , 2003 .

[44]  S. Park,et al.  Reduction of transglutaminase 2 expression is associated with an induction of drug sensitivity in the PC-14 human lung cancer cell line , 1999, Journal of Cancer Research and Clinical Oncology.

[45]  Douglas B. Evans,et al.  The Nuclear Factor-κB RelA Transcription Factor Is Constitutively Activated in Human Pancreatic Adenocarcinoma Cells , 1999 .

[46]  M J May,et al.  NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. , 1998, Annual review of immunology.

[47]  S. Oliverio,et al.  "Tissue" transglutaminase and apoptosis. , 1998, Advances in biochemical engineering/biotechnology.